CAJ | 학술논문

目的评价原位肝移植治疗胆管细胞癌的疗效,并分析影响预后的因素.方法回顾性分析上海长征医院2001年12月至2006年12月问接受OLT的234例肝癌患者的临床资料,其中胆管细胞癌(cholangiocarcinoma,CC)患者6例,包括肝内胆管癌4例,肝门部胆管癌2例.结果 6例患者随访1～56个月,死亡5例(肿瘤复发2例,严重并发症3例).患者的0.5、1和2年累积存活率分别为4/6,3/6和1/6,无瘤存活率分别为3/6,2/6和1/6,患者的平均及无瘤生存时间均为(14±4)个月.结论胆管细胞癌肝移植患者预后较差,须谨慎对待.
목적 평개원위간이식치료담관세포암적료효,병분석영향예후적인소.방법 회고성분석상해장정의원2001년12월지2006년12월문접수OLT적234례간암환자적림상자료,기중담관세포암(cholangiocarcinoma,CC)환자6례,포괄간내담관암4례,간문부담관암2례.결과 6례환자수방1～56개월,사망5례(종류복발2례,엄중병발증3례).환자적0.5、1화2년루적존활솔분별위4/6,3/6화1/6,무류존활솔분별위3/6,2/6화1/6,환자적평균급무류생존시간균위(14±4)개월.결론 담관세포암간이식환자예후교차,수근신대대.
Objective To evaluate the therapeutic effects of liver transplantation (LT) for cholangiocarcinoma(CC)and analyze the prognostic factors.Methods From December 2001 to December 2006,234 patients receiving LT for hepatic carcinoma in our institute were enrolled as a basis of comparative study for 6 CC patients undergoing LT during the same period.Results These 6 patients were followed-up from 1 to 56 months.Five patients died and one recurred.The 0.5-,1-and 2-year patient cumulative survival rates were 4/6,3/6 and 1/6,respectively.The 0.5-,1-and 2-year tumor-free survival rates were 3/6,2/6 and 1/6,respectively.The average patient or tumor-free survival time were both(14±4) months.Conclusion The prognosis of cholangioearcinoma patients after LT iS poor.